Becton, Dickinson and Company

BDX

$187.62

+0.05%

2026-09-03 16:00:03 EDT+$0.10

Healthcare

Medical - Instruments & Supplies

NYSE

Active Trading

Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum ...

Price Action of BDX

$187.62

+0.05%+$0.10

High—

Low—

52W High-2.8%

Rel. vol—

Interval

Range6.5h

Volume—SMA5SMA10

—

Becton, Dickinson and Company (BD) is a prominent global medical technology company with a purpose of advancing the world of health. Established in 1897 by Maxwell Becton and Fairleigh S. Dickinson, BD has grown to employ over 72,000 people and operates in more than 50 countries, delivering billions of products ...Becton, Dickinson and Company (BD) is a prominent global medical technology company with a purpose of advancing the world of health. Established in 1897 by Maxwell Becton and Fairleigh S. Dickinson, BD has grown to employ over 72,000 people and operates in more than 50 countries, delivering billions of products annually. The company is headquartered in Franklin Lakes, New Jersey, and listed on the New York Stock Exchange under the symbol BDX. BD's operations are organized into three main segments. The BD Medical segment focuses on medication management and drug delivery, offering a comprehensive range of products including IV catheters, syringes, needles, infusion systems, and diabetes care products. BD Life Sciences provides diagnostic and research tools such as specimen collection systems, automated microbiology testing, flow cytometry, and molecular diagnostics. The BD Interventional segment delivers specialized surgical and interventional products for hernia repair, biosurgery, surgical infection prevention, and urology and critical care. Financially, BD has a market capitalization of approximately $48.6 billion, with a price-to-earnings ratio around 53. The company generates revenue of about $20 billion annually, with a gross profit margin of 46.1% and an operating margin of 9.8%. Despite a net profit margin of only 4.5%, BD maintains a strong free cash flow, investing in research and development (5.5% of revenue) and marketing. The company has a significant debt load, with a debt-to-equity ratio of 0.69, but manages its obligations with an interest coverage ratio of 3.77. BD's leadership is headed by CEO and Chairman Tom Polen, who has been instrumental in driving innovation and strategic acquisitions. The company is committed to addressing global health challenges, with a focus on medication safety, infection prevention, and chronic disease management. Through its diverse portfolio and global reach, BD continues to play a critical role in the healthcare ecosystem, aiming to improve patient outcomes and reduce healthcare costs.ExpandCollapse

Founded

1897

Employees

72000

CEO

Thomas E. Polen Jr.

Full Name

Becton, Dickinson and Company

Sector

Healthcare

Industry

Medical - Instruments & Supplies

ROE

3.79%

Market Cap

$51.70B

Current Ratio

0.87

WACC

5.33%

ROIC

4.46%

Contact Information

https://www.bd.com

201 847 6800

1 Becton Drive, Franklin Lakes, NJ 07417-1880

Key Metrics of BDX

Snapshot

Latest / TTM · 6 periods

Market Cap

$51.70B

ROCE

5.0%

EV / EBITDA

17.40x

-0.5% YoY

FCF Yield

5.0%

-1.3% YoY

Cash Conversion Cycle

149.2d

Current Ratio

0.87

Quick take

TTM —

Current ratio below 1.0

Negative working capital

Financial Highlights of BDX

Profitability trend

Latest / TTM · 6 periods

Gross Margin

46.1%

Net Margin

4.5%

P/E Ratio

56.51x

n/a

Debt / Equity

0.69

n/a

Current Ratio

0.87

Dividend Yield

2.0%

Understanding

TTM —

Current ratio below 1.0

Calendar of BDX

Upcoming

Sep 9, 2026In 5 days
Ex-dividend date
$4.19 per share
Sep 30, 2026In 26 days
Dividend payment
$4.19 per share
Sep 30, 2026In 26 days
FY2026 · Estimated annual results
Est. EPS $12.67 · Revenue $19.29B · 8 analysts
Dec 30, 2026
Q1 FY2027 · Estimated results
Est. EPS $2.73 · Revenue $4.58B · 6 analysts

Recent history

Aug 6, 2026
Q3 FY2026 · Results reported
EPS $1.37 · Revenue $4.98B
View filing
May 7, 2026
Q2 FY2026 · Results reported
EPS $-1.11 · Revenue $4.71B
View filing
Feb 9, 2026
Q1 FY2026 · Results reported
EPS $1.34 · Revenue $5.25B
View filing
Nov 25, 2025
FY2025 · Annual results
EPS $5.83 · Revenue $21.84B
View filing
Jun 30, 2025
Q3 FY2025 · Results reported
EPS $2.00 · Revenue $5.51B
Mar 31, 2025
Q2 FY2025 · Results reported
EPS $1.07 · Revenue $5.27B

Financial Statements of BDX

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$21.8B	+8.2%	+5.7%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$1.7B	-1.6%	+221.2%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+45.4%	+0.5%	+1.7%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	+11.8%	-0.6%	+567.2%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	+7.7%	-9.1%	+214.7%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$2.7B	-13.1%	-6.8%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	+12.2%	-19.7%	-11.8%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	75.5%	-9.4%	-3.9%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	1.11x	-4.7%	-8.1%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$55.3B	-3.4%	-0.2%

Actual vs Estimate

A Sep 30Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	5.83 vs 11.30	-48.4%	1.37 vs 3.14	-56.4%
Revenue Surprise	$21.8B vs $21.9B	-0.1%	$5.0B vs $4.9B	+2.0%

Insider Transactions of BDX

Acquisitions (A)

Since Jul 27, 2026

Disposals (D)

Since Jul 27, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Aug 26, 2026	Feld Michael	officer: EVP, Chief Revenue Officer	Common Stock	D	165	$188.49
Aug 20, 2026	Feld Michael	officer: EVP, Chief Revenue Officer	Common Stock	D	1,049	—
Aug 13, 2026	Polen Thomas E Jr	director, officer: Chairman, CEO and President	Common Stock	A	43,278	$167.25
Aug 13, 2026	Polen Thomas E Jr	director, officer: Chairman, CEO and President	Common Stock	D	39,126	$185.00
Aug 13, 2026	Polen Thomas E Jr	director, officer: Chairman, CEO and President	Common Stock	D	4,152	$185.00

Earnings Call Transcript of BDX

1 transcript segments

Q3 2026

Unknown Speaker

Operator: Hello, and welcome to BD's Third Fiscal Quarter 2026 Earnings Call. At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at (800) 688-9445 for domestic calls and area code +1 402-220-1371 for international calls. [Operator Instructions] I will now turn the call over to Shawn Bevec, Senior Vice President, Investor Relations. Please go ahead. Shawn Bevec: Good morning, and welcome to BD's earnings call. I'm Shawn Bevec, Senior Vice President of Investor Relations. Thank you for joining us. This call is being made available via audio webcast at bd.com. Earlier this morning, BD released its results for the third quarter of fiscal 2026. The press release and presentation can be accessed on the IR website at investors.bd.com. Leading today's call are Tom Polen, BD's Chairman, Chief Executive Officer and President; and Vitor Roque, Executive Vice President and Chief Financial Officer. Before we get started, I want to remind you that we will be making forward-looking statements. You can read the disclaimer in our earnings release and the disclosures in our SEC filings on our Investor Relations website. Unless otherwise specified, all comparisons will be made on a year-on-year basis versus the relevant fiscal period. Revenue percentage changes are on an FX-neutral basis unless otherwise noted. Also, references to adjusted EPS refer to adjusted diluted EPS. Financials discussed here and included in the earnings release and 10-Q are presented on a continuing operations basis. Prior periods have been recast to reflect the spin-off of our Life Sciences business in combination with Waters, which is now accounted for as discontinued operations. Reconciliations between GAAP and non-GAAP measures are included in the appendices of the earnings release and presentation. With that, I will turn it over to Tom. Thomas Polen: Thank you, Shawn, and good morning, everyone. We delivered a strong third quarter with revenue, adjusted operating margin and adjusted EPS all ahead of our expectations. This was our first full quarter operating as New BD. And more importantly, the quality of this performance reflects our more focused portfolio beginning to demonstrate the growth and earnings potential we designed it to deliver. Performance was broad-based, reflecting commercial momentum across our key growth platforms, strong operational execution and the expanding impact of BD Excellence. Revenue was $5 billion, up 4.4% with more than 90% of the portfolio delivering high single-digit growth. Performance continues to be driven by ongoing structural improvements across our key growth platforms, where we've been focused on enhancing commercial execution and driving product innovation. This includes double-digit growth across biologic drug delivery, advanced patient monitoring, PureWick and advanced tissue regeneration, along with strong performance in peripheral vascular …

Leadership Team of BDX

11 executives

Name	Title	Compensation	Gender	Year Born	Status
Thomas E. Polen Jr.	President, Chief Executive Officer & Chairman	USD 3,588,724	Male	1973	Active
Michael C. Feld	Executive VP & Chief Revenue Officer	USD 1,910,642	Male	1981	Active
Vitor Roque	Executive Vice President & Chief Financial Officer	USD 1,777,376	Male	1983	Active
Michael Garrison	Executive VP & President of Medical Segment and BioPharma Systems Segments	USD 1,360,526	Male	1970	Active
Meera Gopalakrishnan	Senior VP & Global Chief Marketing Officer	—	Female	—	Active
Shawn C. Bevec	Senior Vice President of Investor Relations	—	Male	—	Active
Carla Burigatto	Senior Vice President & Chief Communications Officer	—	—	—	Active
Joseph Smith	Senior Vice President & Chief Scientific Officer	—	—	—	Active
Denise Fleming	Executive Vice President & Chief Information Officer	—	Female	1971	Active
Elizabeth McCombs	Executive Vice President & Chief Technology Officer	—	Female	1977	Active
Lanesha T. Minnix	Executive Vice President & General Counsel	—	Female	1975	Active

Recent News of BDX

GuruFocus8/12/2026Neutral

BDX DCF Analysis: Intrinsic Value $141 vs Price $181

On August 12, 2026, we delve into the DCF analysis for Becton Dickinson and Co (BDX), a company that has shown notable price performance recently, with a year-to-

PRNewsWire8/12/2026Neutral

BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial

Enrollment completed in the first large-scale randomized study evaluating Phasix™ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgery FRANKLIN LAKES, N.J., Aug. 12, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with successful completion of enrollment in the PREVENT clinical trial evaluating Phasix™ Mesh for the prevention of incisional hernias.

GuruFocus8/11/2026Neutral

First Eagle Investment Buys Becton Dickinson & Co (BDX) -- Shares Look 6% Undervalued on GF Value

On June 30, 2026, First Eagle Investment (Trades, Portfolio) executed a significant add transaction for Becton Dickinson and Co (NYSE: BDX), increasing the firm's

24/7 Wall Street8/10/2026Neutral

We Said These 4 Dividend Aristocrats Could Soar. Here's How They Did, Plus 3 New Picks.

About a year ago, 24/7 Wall St. flagged four overlooked Dividend Aristocrats as stealth growth plays, arguing that boring income names carried real upside if the market ever noticed.

GuruFocus8/7/2026Neutral

Becton Dickinson & Co (BDX) (Q3 2026) Earnings Call Highlights: Strong Revenue Growth and Raised Guidance Amid Tariff Pressures

Revenue: $5 billion, up 4.4% on an FX-neutral basis.Adjusted Operating Margin: 24.9%, down 130 basis points versus the prior year.Adjusted Gross Margin: 54.3%,

Historical Employee Count of BDX

Current

72,000

Change

-2.70%

Minimum

72,000

Maximum

77,000

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Sep 30, 2025	72,000	10-K	Nov 25, 2025	View
Sep 30, 2024	74,000	10-K	Nov 27, 2024	View
Sep 30, 2023	73,000	10-K	Nov 21, 2023	View
Sep 30, 2022	77,000	10-K	Nov 22, 2022	View
Sep 30, 2021	75,000	10-K	Nov 24, 2021	View

Related stocksMedical - Instruments & Supplies

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Becton, Dickinson and Company